DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for janus kinase-3 deficiency — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleJanus kinase-3 deficiency maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for janus kinase-3 deficiency is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
Janus kinase 3 (JAK3) — JAK3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet izadrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3LXL · 1.74 Å · ligand 2-TERT-BUTYL-9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLINE-7-ONE (IZA). Experimental structure, not a prediction.
What the evidence adds up to
Janus kinase 3 (Jak3) deficiency is a cause of severe combined immunodeficiency (SCID). Jak3 is expressed primarily in B, T and natural killer cells and is activated through the gamma-c chain of interleukin-2-like cytokine receptors (IL-2, -4, -7, -9, -15, -21). In humans, Jak3 deficiency produces defects restricted to the immune system. No direct structural information for any portion of the Jak family kinases had been reported as of 2004, though crystallographic studies of the Jak3 kinase domain and the Jak3-Ferm:IL-2gamma-c interaction were underway.
Janus kinase inhibitors (JAKis) are small molecules that target Janus kinase proteins on the cell membrane. Their pharmacodynamics are dose-dependent and vary by indication due to variable regulation of the JAK/STAT signalling pathway and pharmacokinetic conditions. The 2022 review states that only clinical trial data in defined indications are suitable for evaluating efficacy and safety, and that uncritical extrapolation from studies of other indications should be made only with due caution. The 2024 reviews discuss JAKis in the context of dermatological conditions such as alopecia areata, psoriasis, vitiligo, and lichen planus, and note that these drugs carry a boxed warning. No clinical trial data for JAK inhibitors in Jak3 deficiency are reported in any of the provided abstracts.
What remains missing for Jak3 deficiency is any clinical trial testing of JAK inhibitors in patients with the condition, including data on dosing, efficacy, or safety. The structural work needed to design selective inhibitors of Jak3 catalytic activity or of the Jak3:IL-2gamma-c interaction was still in progress as of 2004, and no subsequent results from that work are given here. No patient stratification, funding for trials, or trial design specific to Jak3 deficiency is described.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
JDDG Journal der Deutschen Dermatologischen Gesellschaft · 2022 · 21 citations · open access
Pharmacology of inhibitors of Janus kinases – Part 2: Pharmacodynamics
AbstractAs small molecules, the Janus kinase inhibitors have different, dose-dependent pharmacological binding selectivities, which, however, do not allow reliable statements about the clinical specificity of desired or side effects. It is therefore of particular importance to recognize that the pharmacodynamics of the individual Janus kinase inhibitors as a function of the treated indication is essentially determined by variable levels of regulation of the JAK/STAT signaling pathway and the pharmacokinetic conditions. Against this background, it becomes clear that only clinical trial data in defined indications are suitable for evaluating the efficacy and safety of Janus kinase inhibitors. An uncritical extrapolation of observations regarding efficacy and safety from studies of other indications should therefore only be made with due caution.
DOAJ (DOAJ: Directory of Open Access Journals) · 2024 · 0 citations · open access
The Emerging World of JAK Inhibitors
AbstractThe Janus Kinase inhibitors are a new emerging class of small molecules. These target the Janus Kinase proteins located on the cell membrane. Janus Kinase proteins regulate the cellular transcription of several proteins and act as mediators in several cytokine pathways. Dysregulation in these cytokine pathways is responsible for disorders like alopecia areata, psoriasis, vitiligo, lichen planus, and more in dermatology. Contrary to the injectable biologics, these Janus kinase inhibitors can be taken per oral route and have greater patient acceptability. In this review, we seek to discuss the various indications of Janus Kinase inhibitors and their side effects. We also strive to discuss the monitoring for this class of drugs.
Journal of Drugs in Dermatology · 2024 · 0 citations
The ABCs of JAKis: A Clinician's Guide to Safety and Monitoring of the Systemic JAK Inhibitors
AbstractJanus kinase inhibitors (JAKis) have recently emerged in the arsenal of tools to treat dermatological conditions. However, there are some concerns regarding these treatments due to their boxed warning. Here we discuss the safe and effective use of JAKs for the treatment of a wide variety of dermatologic conditions. We will also discuss monitoring guidelines. J Drugs Dermatol. 2024;23(10):852-856. doi:10.36849/JDD.8073.
AbstractAbstract Janus Kinase 3 (Jak3) plays an essential role in hematopoietic signaling. Primarily expressed in B-, T- and Natural killer cells, it is activated through the γc chain of interleukin-2 like cytokine receptors (IL-2, -4, -7, -9, -15, -21). Deficiency of catalytically active Jak3 or disruption of the Jak3:IL-2γc interaction results in severe combined immunodeficiency (SCID). Jak3-deficient humans demonstrate defects restricted to the immune system, suggesting that selective inhibition of Jak3 catalytic activity or interruption of the Jak3:IL-2γc interaction are potentially exploitable strategies to achieve immunosuppression. Jak kinases contain four defined regions; a catalytically active carboxy-terminal kinase, a pseudo-kinase, a SH2-like region and a N-terminal Ferm domain. To date, no direct structural information has been reported for portions of any of the Jak family kinases. Structural studies are underway to define crystallographically the kinase domain of Jak3 and the Jak3-Ferm:IL-2γc interaction. Structural insights into the mechanism of Jak activation and routes to specific inhibition will be discussed.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
